Age and Ageing,
Journal Year:
2023,
Volume and Issue:
52(10)
Published: Sept. 4, 2023
Parkinson's
disease
(PD)
is
the
second
most
common
neurodegenerative
disorder
after
Alzheimer's
disease.
Ageing
considered
to
be
greatest
risk
factor
for
PD,
with
a
complex
interplay
between
genetics
and
environment.
With
population
ageing,
prevalence
of
PD
expected
escalate
worldwide;
thus,
it
utmost
importance
reduce
burden
PD.
To
date,
there
are
no
therapies
cure
disease,
current
treatment
strategies
focus
on
management
symptoms.
Older
adults
often
have
multiple
chronic
diseases
geriatric
syndromes,
which
further
complicates
Healthcare
systems
care
models
necessary
address
broad
needs
older
patients
largely
unavailable.
In
this
New
Horizon
article,
we
discuss
various
aspects
from
an
ageing
perspective,
including
management.
We
highlight
recent
advancements
in
new
potential
improve
patient's
quality
life.
Journal of Personalized Medicine,
Journal Year:
2024,
Volume and Issue:
14(1), P. 112 - 112
Published: Jan. 19, 2024
Parkinson’s
disease
is
the
second
most
common
neurodegenerative
and
increasing
in
incidence.
The
combination
of
motor
non-motor
symptoms
makes
this
a
devastating
for
people
with
their
care
givers.
characterised
by
mitochondrial
dysfunction
neuronal
death
substantia
nigra,
reduction
dopamine,
accumulation
α-synuclein
aggregates
neuroinflammation.
microbiome–gut–brain
axis
also
important
disease,
involved
spread
inflammation
aggregated
α-synuclein.
mainstay
treatment
dopamine
replacement
therapy,
which
can
reduce
some
signs.
There
need
additional
options
to
supplement
available
medications.
Photobiomodulation
(PBM)
form
light
therapy
that
has
been
shown
have
multiple
clinical
benefits
due
its
enhancement
electron
transport
chain
subsequent
increase
membrane
potential
ATP
production.
PBM
modulates
cellular
signalling
inflammation.
Clinically,
used
decades
improve
wound
healing,
treat
pain,
swelling
heal
deep
tissues.
Pre-clinical
experiments
indicated
signs
provide
neuroprotection.
This
effect
seen
whether
directed
head
animal
or
other
parts
body
(remotely).
A
small
number
trials
given
weight
possibility
using
both
may
potentially
slow
progression.
Exploration of Neuroprotective Therapy,
Journal Year:
2024,
Volume and Issue:
unknown, P. 119 - 147
Published: April 16, 2024
Degeneration
and
dysfunction
of
neurons
in
the
brain
are
hallmarks
neurodegenerative
diseases.
Over
past
decades,
significant
efforts
have
been
devoted
to
development
validation
biomarkers
for
The
range
diversity
central
nervous
system
(CNS)
diseases
has
continued
expand,
encompassing
biofluid-based
sources
such
as
blood
or
cerebrospinal
fluid
(CSF),
nucleic
acids,
tissues,
imaging.
While
imaging
tissue
biopsy-based
markers
continually
being
identified
their
applications
expanding,
they
do
limitations
compared
with
RNA
protein
biomarkers.
This
review
comprehensively
summarizes
various
biomarkers,
including
microRNA
(miRNA),
long
noncoding
(lncRNA),
circulating
miRNA
(cimiRNA),
proteins,
context
CNS
disorders.
In
addition,
emphasizes
existing
challenges
associated
use
both
clinical
practice
research
on
conclusion,
this
provides
an
insightful
overview
diseases,
underscoring
crucial
role
biomarker
combating
these
debilitating
conditions.
article
also
highlights
future
related
implementation
novel
trials,
thereby
contributing
ongoing
advance
understanding
management
MedComm,
Journal Year:
2024,
Volume and Issue:
5(7)
Published: July 1, 2024
Abstract
The
cerebellum
is
crucial
for
both
motor
and
nonmotor
functions.
Alzheimer's
disease
(AD),
alongside
other
dementias
such
as
vascular
dementia
(VaD),
Lewy
body
(DLB),
frontotemporal
(FTD),
well
neurodegenerative
diseases
(NDs)
like
Parkinson's
(PD),
amyotrophic
lateral
sclerosis
(ALS),
Huntington's
(HD),
spinocerebellar
ataxias
(SCA),
are
characterized
by
specific
non‐specific
neurodegenerations
in
central
nervous
system.
Previously,
the
cerebellum's
significance
these
conditions
was
underestimated.
However,
advancing
research
has
elevated
its
profile
a
critical
node
pathology.
We
comprehensively
review
existing
evidence
to
elucidate
relationship
between
aforementioned
diseases.
Our
findings
reveal
growing
of
unequivocally
establishing
link
AD,
forms
dementia,
NDs,
supported
clinical
evidence,
pathological
biochemical
profiles,
structural
functional
neuroimaging
data,
electrophysiological
findings.
By
contrasting
cerebellar
observations
with
those
from
cerebral
cortex
hippocampus,
we
highlight
distinct
role
processes.
Furthermore,
also
explore
emerging
therapeutic
potential
targeting
treatment
This
underscores
importance
diseases,
offering
new
insights
into
mechanisms
novel
strategies.
Materials Today Bio,
Journal Year:
2025,
Volume and Issue:
31, P. 101457 - 101457
Published: Jan. 5, 2025
Central
nervous
system
(CNS)
diseases
are
a
major
cause
of
disability
and
death
worldwide.
Due
to
the
blood-brain
barrier
(BBB),
drug
delivery
for
CNS
is
extremely
challenging.
Nano-delivery
systems
can
overcome
limitations
BBB
deliver
drugs
CNS,
improve
ability
target
brain
provide
potential
therapeutic
methods
diseases.
At
same
time,
choice
different
(bypassing
or
crossing
BBB)
further
optimize
effect
nano-drug
system.
This
article
reviews
nano-delivery
way
enters
brain.
Different
kinds
nanoparticles
were
discussed
in
depth.
CNS Neuroscience & Therapeutics,
Journal Year:
2020,
Volume and Issue:
26(10), P. 997 - 1009
Published: June 29, 2020
Abstract
The
fight
against
neurodegenerative
diseases,
Alzheimer
disease
and
Parkinson's
(PD),
is
a
challenge
of
the
21st
century.
low
efficacy
treating
patients
due
to
late
diagnosis
start
therapy,
after
degeneration
most
specific
neurons
depletion
neuroplasticity.
It
believed
that
development
early
(ED)
preventive
treatment
will
delay
onset
symptoms.
This
review
evaluates
methodologies
for
developing
ED
PD.
Since
PD
systemic
disease,
certain
precedes
nigrostriatal
dopaminergic
control
motor
function,
current
methodology
based
on
searching
biomarkers,
such
as
premotor
symptoms
changes
in
body
fluids
(BF)
patients.
However,
all
attempts
develop
were
unsuccessful.
Therefore,
it
proposed
enhance
by
(i)
selecting
among
biomarkers
found
BF
at
clinical
stage
those
are
characteristics
animal
models
preclinical
stage,
(ii)
subjects
prodromal
selected
detecting
failure
system.
Moreover,
new
was
using
provocative
test,
which
successfully
used
internal
medicine.
Translational Neurodegeneration,
Journal Year:
2021,
Volume and Issue:
10(1)
Published: Oct. 18, 2021
Abstract
Parkinson’s
disease
(PD)
is
a
common
neurodegenerative
disorder
that
primarily
affects
the
elderly.
While
etiology
of
PD
likely
multifactorial
with
involvement
genetic,
environmental,
aging
and
other
factors,
α-synuclein
(α-syn)
pathology
pivotal
mechanism
underlying
development
PD.
In
recent
years,
astrocytes
have
attracted
considerable
attention
in
field.
Although
perform
variety
physiological
functions
brain,
they
are
mediators
α-syn
toxicity
since
internalize
released
from
damaged
neurons,
this
triggers
an
inflammatory
response,
protein
degradation
dysfunction,
mitochondrial
dysfunction
endoplasmic
reticulum
stress.
Astrocytes
indispensable
coordinators
background
several
genetic
mutations,
including
PARK7,
GBA1,
LRRK2,
ATP13A2,
PINK1,
PRKN
PLA2G6
.
As
most
abundant
glial
cells
functional
can
be
replenished
even
converted
to
neurons.
review,
we
discuss
astrocyte
emphasis
on
modulation
conclude
replenishment
valuable
therapeutic
approach
